Drugs / AdcuCD40L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00328887 | Nov 2004 → Jul 2010 | neoplasm of esophagus | Weill Medical College of Cornell University | Withdrawn | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00504322 Comparator | Jul 2011 | neoplasm of esophagus | Weill Medical College of Cornell University | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AdcuCD40L | “This will be accomplished by endoscopic administration to the tumors of AdcuCD40L, an adenovirus gene transfer vector expressing the coding sequence of the human CD40L cDNA.” NCT00328887 ↗ |
| Known as | CD40 Ligand Gene (AdcuCD40L) | “CD40 Ligand Gene (AdcuCD40L)” NCT00328887 ↗ |
| Route | Other | “gene transfer, intratumoral administration” NCT00328887 ↗ |
| Target | CD40LG | “AdcuCD40L, an adenovirus gene transfer vector expressing the coding sequence of the human CD40L cDNA.” NCT00328887 ↗ |